Jörg Dietrich

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Chemotherapy associated central nervous system damage
    Jörg Dietrich
    Department of Neurology, MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street Yawkey 9E, Boston, Massachusetts 02114, USA
    Adv Exp Med Biol 678:77-85. 2010
  2. pmc Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system
    Ruolan Han
    Department of Biomedical Genetics and University of Rochester Stem Cell and Regenerative Medicine Institute, University of Rochester Medical Center, Elmwood Avenue, Rochester, NY 14642, USA
    J Biol 7:12. 2008
  3. doi request reprint Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy
    Jörg Dietrich
    Department of Neurology, Division of Neuro Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Oncologist 13:1285-95. 2008
  4. doi request reprint Glioma stem cell signaling: therapeutic opportunities and challenges
    Jörg Dietrich
    Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 10:709-22. 2010
  5. doi request reprint Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas
    Jörg Dietrich
    Department of Neurology, Brigham and Women s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
    Nat Clin Pract Oncol 5:393-404. 2008
  6. pmc CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo
    Joerg Dietrich
    Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Biol 5:22. 2006
  7. pmc Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis
    Michelle Monje
    Department of Neurology, Division of Child Neurology, Stanford University Medical Center, 750 Welch Road, Suite 317, Palo Alto, CA 94304, USA
    Behav Brain Res 227:376-9. 2012
  8. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
  9. doi request reprint Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Shota Tanaka
    Stephen E and Catherine Pappas Center for Neuro Oncology, Boston, MA 02114, USA
    Nat Rev Clin Oncol 10:14-26. 2013
  10. ncbi request reprint Role of endogenous neural stem cells in neurological disease and brain repair
    Jörg Dietrich
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Adv Exp Med Biol 557:191-220. 2006

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Chemotherapy associated central nervous system damage
    Jörg Dietrich
    Department of Neurology, MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street Yawkey 9E, Boston, Massachusetts 02114, USA
    Adv Exp Med Biol 678:77-85. 2010
    ....
  2. pmc Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system
    Ruolan Han
    Department of Biomedical Genetics and University of Rochester Stem Cell and Regenerative Medicine Institute, University of Rochester Medical Center, Elmwood Avenue, Rochester, NY 14642, USA
    J Biol 7:12. 2008
    ..Nor are there any animal models that could enable the study of this important problem...
  3. doi request reprint Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy
    Jörg Dietrich
    Department of Neurology, Division of Neuro Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Oncologist 13:1285-95. 2008
    ....
  4. doi request reprint Glioma stem cell signaling: therapeutic opportunities and challenges
    Jörg Dietrich
    Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 10:709-22. 2010
    ..This review summarizes important signaling pathways employed by both normal and cancer stem cells and highlights promising molecular-targeted therapies interfering with those signaling pathways in malignant gliomas...
  5. doi request reprint Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas
    Jörg Dietrich
    Department of Neurology, Brigham and Women s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
    Nat Clin Pract Oncol 5:393-404. 2008
    ..This Review summarizes recent advances in the basic understanding of neural stem cell and cancer stem cell biology and the progress towards translating these novel concepts into the clinic...
  6. pmc CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo
    Joerg Dietrich
    Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Biol 5:22. 2006
    ..The underlying cellular basis for these adverse effects is poorly understood...
  7. pmc Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis
    Michelle Monje
    Department of Neurology, Division of Child Neurology, Stanford University Medical Center, 750 Welch Road, Suite 317, Palo Alto, CA 94304, USA
    Behav Brain Res 227:376-9. 2012
    ....
  8. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
    ..nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. ..
  9. doi request reprint Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Shota Tanaka
    Stephen E and Catherine Pappas Center for Neuro Oncology, Boston, MA 02114, USA
    Nat Rev Clin Oncol 10:14-26. 2013
    ..In addition, we emphasize current biomarkers relevant to the management of patients with glioblastoma...
  10. ncbi request reprint Role of endogenous neural stem cells in neurological disease and brain repair
    Jörg Dietrich
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Adv Exp Med Biol 557:191-220. 2006
    ..The following years will have to show how we can influence andmodulate endogenous repair nisms by increasing the cellular plasticity in the young and aged CNS...
  11. pmc Mathematical and experimental approaches to identify and predict the effects of chemotherapy on neuroglial precursors
    Ollivier Hyrien
    Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cancer Res 70:10051-9. 2010
    ..These changes of precursor cell function in the chemotherapy-exposed brain may have profound clinic implications...
  12. doi request reprint Imaging findings in cancer therapy-associated neurotoxicity
    Isabel C Arrillaga-Romany
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA, USA
    Semin Neurol 32:476-86. 2012
    ..Identification of causative agents and appropriate distinction between treatment-related toxicity and tumor-associated complications are critical steps to improve treatment monitoring and overall patient care...
  13. pmc Corticosteroids in brain cancer patients: benefits and pitfalls
    Jörg Dietrich
    MGH Cancer Center and Center for Regenerative Medicine, Harvard Medical School, Boston, MA, USA
    Expert Rev Clin Pharmacol 4:233-42. 2011
    ..This article summarizes current concepts of using corticosteroids in brain cancer patients and highlights potential pitfalls in their effects on both tumor and neural progenitor cells...
  14. pmc Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
    Jörg Dietrich
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Expert Opin Investig Drugs 18:1549-57. 2009
    ..Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas...
  15. ncbi request reprint Developing concepts in neural stem cells
    Joerg Dietrich
    Dept of Biomedical Genetics, University of Rochester, 601 Elmwood Avenue, Box 633, Rochester, NY 14642, USA
    Trends Neurosci 25:129-31. 2002
    ..Stem Cells in the Mammalian Brain: the 4th Brain Research Interactive Symposium, at the 2001 Annual Conference of the Society for Neuroscience, San Diego, CA, USA from November 8-10 2001...
  16. ncbi request reprint EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy
    Jörg Dietrich
    Department of Biomedical Genetics, Aab Institute, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Nat Med 11:277-83. 2005
    ..This raises the possibility that a deficiency in astrocyte function may contribute to the loss of white matter in VWM leukodystrophy...
  17. doi request reprint Emerging antiangiogenic treatments for gliomas - efficacy and safety issues
    Jörg Dietrich
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 21:736-44. 2008
    ..To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of these agents...
  18. ncbi request reprint Characterization of A2B5+ glial precursor cells from cryopreserved human fetal brain progenitor cells
    Joerg Dietrich
    Department of Biomedical Genetics, University of Rochester, Rochester, New York 14642, USA
    Glia 40:65-77. 2002
    ....
  19. ncbi request reprint Infection with an endemic human herpesvirus disrupts critical glial precursor cell properties
    Joerg Dietrich
    Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Neurosci 24:4875-83. 2004
    ....
  20. ncbi request reprint Intersections between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage
    Mark Noble
    Dept of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 633, Rochester, NY 14642, USA
    Trends Neurosci 25:103-7. 2002
    ....
  21. ncbi request reprint Glutamate transporter expression and function in human glial progenitors
    Nicholas J Maragakis
    Department of Neurology and Neuroscience, Johns Hopkins University, Meyer 6 109, 600 N Wolfe Street, Baltimore, MD 21287 5953, USA
    Glia 45:133-43. 2004
    ....
  22. ncbi request reprint The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity
    Mark Noble
    Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 633, Rochester, NY 14642, USA
    Trends Neurosci 27:148-54. 2004
    ....